New drug VNRX-7145 passes first safety check in healthy people
NCT ID NCT04243863
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This early-stage study tested the safety of a new drug called VNRX-7145 in 83 healthy adults aged 18 to 45. Participants received either a single dose or multiple doses over 10 days to see how the drug moves through the body and if it causes any side effects. The goal was not to treat any disease, but to gather important safety information before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Worldwide Clinical Trials Early Phase Services, LLC
San Antonio, Texas, 78217, United States
Conditions
Explore the condition pages connected to this study.